Drugs and Devices

Effectiveness of abaloparatide in patients with osteoporosis

Subcutaneous abaloparatide reduces the risk of new vertebral and nonvertebral fractures over 18 months in patients with osteoporosis, according to a study in JAMA. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares